About UsTransCode Therapeutics is a Boston-based biotechnology company focused on oncology. TransCode's lofty goal is delivering a cancer-free future for all cancer patients. Our core belief is that cancer can be overcome through the intelligent design and efficient delivery of targeted therapeutics.
Until now, success with targeting genetic markers that are the primary drivers of cancer onset, progression and recurrence has been hampered by the challenge of delivery – the ability to engage these known targets in the cells and tissues of interest while minimizing off-target effects in other tissues. Small, non-coding strands of RNA (microRNAs) have been identified as a significant player in the pathology of cancer and metastasis.Our research observed that miRNA-10b acts as a master regulator of the viability of metastatic tumor cells. Our lead therapeutic candidate, TTX-MC138, targets this microRNA, expressed in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others. Learn more about the Science behind TTX and about our Pipeline. |
|
|
TTX is an investigational platform encompassing therapeutic candidates (including TTX-MC138) and diagnostics which remain in development. Their safety and efficacy have not yet been evaluated by the FDA or any other regulatory agency.
|
© TRANSCODE THERAPEUTICS, INC. 2024. ALL RIGHTS RESERVED.